Metastron

Metastron, also known by its chemical name strontium-89 chloride, is a radiopharmaceutical agent used in the treatment of pain associated with metastatic bone cancer. Administered intravenously, Metastron provides palliative care for patients suffering from painful skeletal metastases, which are common in advanced stages of cancer, particularly prostate and breast cancer.

Overview

Metastron is a radioactive isotope of strontium that mimics calcium and selectively targets bone tissue, especially areas with increased bone turnover, such as those affected by metastatic cancer lesions. Once it is administered, strontium-89 is absorbed by the bone matrix, delivering targeted radiation therapy to the metastatic bone sites, which helps to relieve bone pain and improve the quality of life for cancer patients.

Mechanism of Action

The mechanism of action of Metastron involves the emission of beta radiation upon its decay, which has a therapeutic effect on bone metastases. The beta particles emitted are of relatively high energy but short range, ensuring that the radiation is confined to the bone tissue, minimizing exposure to surrounding healthy tissues. This targeted approach helps to reduce the activity of osteoclasts, the cells responsible for bone resorption, thereby alleviating pain and preventing further bone damage.

Indications

Metastron is primarily indicated for the relief of bone pain in patients with skeletal metastases from prostate cancer, breast cancer, and other types of cancer that spread to the bone. It is particularly beneficial for patients with multiple painful sites, offering a non-invasive alternative to external beam radiation therapy.

Administration and Dosage

Metastron is administered as a single intravenous injection. The standard dosage may vary depending on the patient's body weight and overall health status, as well as the extent of bone metastases. A single dose can provide pain relief that lasts for several months, and the treatment can be repeated based on the patient's response and clinical condition.

Side Effects and Precautions

The most common side effects of Metastron treatment include temporary lowering of blood cell counts, which can increase the risk of infection, anemia, and bleeding. Patients may also experience mild to moderate flu-like symptoms following the administration. Due to its radioactive nature, Metastron must be handled and administered by trained medical professionals, and appropriate safety protocols must be followed to protect both the patient and healthcare staff.

Conclusion

Metastron represents a significant advancement in palliative care for cancer patients with painful bone metastases. By specifically targeting metastatic sites in the bone, it offers an effective means of pain management, thereby enhancing the quality of life for many patients. Ongoing research continues to explore the full potential of Metastron and other radiopharmaceuticals in cancer treatment.

Metastron Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski